Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$3.11
-2.2%		$4.08
$2.56
▼
$11.97
$3.92M1.5218,575 shs4,512 shs
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$0.22
$0.14
$0.15
▼
$7.10
$995K1.1286,634 shsN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
$1.52
+12.6%		$2.01
$1.04
▼
$11.08
$3.74M1.221,733 shs2.95 million shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$0.97
-0.7%		$1.09
$0.84
▼
$8.62
$3.42M2.4240,529 shs41,141 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
-2.20%+1.30%-13.85%-50.95%-65.54%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00%0.00%0.00%0.00%+50.79%
Heatwurx Inc. stock logo
PCSA
Heatwurx
+12.59%-5.59%-23.62%-29.63%-87.30%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-0.73%-30.55%+2.68%-38.12%-84.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$3.11
-2.2%		$4.08
$2.56
▼
$11.97
$3.92M1.5218,575 shs4,512 shs
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$0.22
$0.14
$0.15
▼
$7.10
$995K1.1286,634 shsN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
$1.52
+12.6%		$2.01
$1.04
▼
$11.08
$3.74M1.221,733 shs2.95 million shs
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$0.97
-0.7%		$1.09
$0.84
▼
$8.62
$3.42M2.4240,529 shs41,141 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
-2.20%+1.30%-13.85%-50.95%-65.54%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00%0.00%0.00%0.00%+50.79%
Heatwurx Inc. stock logo
PCSA
Heatwurx
+12.59%-5.59%-23.62%-29.63%-87.30%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-0.73%-30.55%+2.68%-38.12%-84.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
1.00
SellN/AN/A
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
0.00
N/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
1.00
SellN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
2.00
Hold$13.851,334.64% Upside

Current Analyst Ratings Breakdown

Latest BIOR, PCSA, SXTP, and ADXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/2/2026
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/21/2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$210K18.22N/AN/A$4.67 per share0.67
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
$892K1.12N/AN/A($36.43) per share-0.01
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A$2.46 per shareN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
$1.11M3.06N/AN/A($5.85) per share-0.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
-$8.12M-$5.94N/AN/AN/AN/A-174.44%-126.47%11/9/2026 (Estimated)
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
-$124.11M-$13.04N/AN/AN/AN/AN/A-332.47%N/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$13.56M-$4.23N/AN/AN/AN/A-394.25%-244.46%10/29/2026 (Estimated)
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$7.36M-$4.82N/AN/AN/A-650.21%N/A-136.81%11/12/2026 (Estimated)

Latest BIOR, PCSA, SXTP, and ADXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$1.00N/AN/AN/AN/AN/A
9/25/2026Q2 2026
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/A-$1.48N/A-$1.48N/A$0.01 million
8/14/2026Q2 2026
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$1.00-$1.19-$0.19-$1.19N/AN/A
8/14/2026Q2 2026
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
-$0.74-$0.90-$0.16-$0.90$0.21 million$0.21 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/AN/AN/AN/AN/A
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/A
0.76
0.76
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
N/A
0.05
0.05
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
0.87
0.87
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
N/A
2.32
1.78

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
16.14%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
43.74%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
7.96%

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
15.00%
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
51.08%
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.50%
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
1.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
31.23 million1.05 millionNot Optionable
Biora Therapeutics, Inc. stock logo
BIOR
Biora Therapeutics
1204.52 million2.21 millionNo Data
Heatwurx Inc. stock logo
PCSA
Heatwurx
122.77 million2.67 millionNot Optionable
60 Degrees Pharmaceuticals Inc. stock logo
SXTP
60 Degrees Pharmaceuticals
33.52 million3.46 millionNot Optionable

Recent News About These Companies

60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock Price Down 0.9% - Time to Sell?
October 8 at 2:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31097907
60 Degrees To Unblind Babesiosis Study In January 2027; Plans FDA Meeting Following Interim Review
October 7 at 5:05 AM  |  rttnews.comhttps://www.rttnews.com/3696903/60-degrees-to-unblind-babesiosis-study-in-january-2027-plans-fda-meeting-following-interim-review.aspx
60 Degrees Pharmaceuticals sets January 2027 babesiosis data readout and plans FDA pre-sNDA meeting
October 7 at 5:05 AM  |  msn.comhttps://www.msn.com/en-us/science/microbiology/60-degrees-pharmaceuticals-sets-january-2027-babesiosis-data-readout-and-plans-fda-pre-snda-meeting/ar-AA2dGktM
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375462/0/en/60-degrees-pharmaceuticals-plans-january-2027-hospitalized-babesiosis-data-readout-will-seek-pre-snda-meeting-with-fda.html
Babesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares Climb
October 6, 2026  |  rttnews.comhttps://www.rttnews.com/3696739/babesiosis-data-readout-today-as-60-degrees-pharmaceuticals-shares-climb.aspx
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
October 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/60-degrees-pharmaceuticals-exyn-technologies-130000374.html
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372857/0/en/60-degrees-pharmaceuticals-announces-date-for-hospitalized-babesiosis-study-interim-data-release-and-key-opinion-leader-webinar.html
60 Degrees Pharma Nears Key Tafenoquine Data Readout In Babesiosis
September 29, 2026  |  rttnews.comhttps://www.rttnews.com/3694776/60-degrees-pharma-nears-key-tafenoquine-data-readout-in-babesiosis.aspx
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/03/3355877/0/en/60-degrees-pharmaceuticals-announces-participation-in-h-c-wainwright-28th-annual-global-investment-conference.html
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345584/0/en/60-degrees-pharmaceuticals-announces-second-quarter-2026-results.html
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
July 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/30/3336358/0/en/60-degrees-pharmaceuticals-inc-announces-private-placement-priced-at-the-market-under-nasdaq-rules.html
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
July 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/29/3335549/0/en/60-degrees-pharmaceuticals-announces-minimum-enrollment-achieved-in-hospitalized-babesiosis-study-interim-data-readout-planned-by-october-6-2026.html
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324057/0/en/60-degrees-pharmaceuticals-announces-exclusive-option-agreement-with-florida-state-university-to-advance-castanospermine-for-tick-borne-diseases.html
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis ...
July 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/60-degrees-pharmaceuticals-announces-positive-recommendation-from-data-safety-monitoring-board-for-b-free-phase-2-study-of-tafenoquine-for-treatment-of-chronic-babesiosis-patients-with-severe-fatigue-1036290098
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320572/0/en/60-degrees-pharmaceuticals-announces-positive-recommendation-from-data-safety-monitoring-board-for-b-free-phase-2-study-of-tafenoquine-for-treatment-of-chronic-babesiosis-patients-.html
60 Degrees Pharmaceuticals (NASDAQ:SXTP) CEO Geoffrey Dow Acquires 7,350 Shares
June 16, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-sxtp-insider-buying-and-selling-2026-06-16/
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
June 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/11/3310432/0/en/60-degrees-pharmaceuticals-signs-exclusive-patent-license-agreement-with-florida-state-university-for-non-prescription-use-of-australian-chestnut-extract-as-a-botanical-supplement.html
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301055/0/en/60-degrees-pharmaceuticals-announces-early-enrollment-of-first-seasonal-patient-in-clinical-trial-of-tafenoquine-for-patients-hospitalized-with-babesiosis.html
HC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)
May 21, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/hc-wainwright-co-downgrades-60-degrees-pharmaceuticals-sxtp/ar-AA23H6gv
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295850/0/en/60-degrees-pharmaceuticals-announces-first-quarter-2026-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics NASDAQ:ADXN

$3.11 -0.07 (-2.20%)
Closing price 10/9/2026 03:58 PM Eastern
Extended Trading
$3.10 0.00 (-0.16%)
As of 10/9/2026 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Biora Therapeutics stock logo

Biora Therapeutics NASDAQ:BIOR

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$1.52 +0.17 (+12.59%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.47 -0.05 (-3.03%)
As of 10/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTP

$0.97 -0.01 (-0.73%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$0.94 -0.03 (-2.94%)
As of 10/9/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas